Novartis is denying a report out of India suggesting it may be looking to retreat from the increasingly competitive market for asthma and COPD drugs and is…

Sanofi is in talks to buy Flexion Therapeutics, a biotech with its lead product awaiting FDA approval, for more than $1 billion, according to a source close to…

Allergan is facing potential fallout from shareholders who say Allergan’s share price has been stung by questionable generics pricing.

The race to snatch up generics maker Stada is heating up—and fast—with multiple players reportedly preparing to jump in, including Chinese drugmakers and,…

Sanofi is prepping the sale of its European generics unit, according to a new report.

Pfizer, which scooped up Bamboo Therapeutics last year in its aim to be a major player in gene therapies, is now looking at building a gene therapy production…

It’s a tough landscape out there for generics makers—particularly the smaller ones. And that has Impax Labs thinking it may want to get a bit bigger.

Valeant’s executives did their darndest to point out the positives in the company’s Q4 earnings, but they couldn’t hide from the picture painted by the numbers.

M&A